South America's Keytruda Market Sees Steady Growth, Driven by Cancer Burden and Expanding Immunotherapy Access
The South America Keytruda Market, encompassing Merck & Co.'s breakthrough immunotherapy drug pembrolizumab, is a segment of increasing importance within the region's oncology landscape. As South American nations grapple with a growing incidence of various cancers, there is an escalating demand for advanced therapeutic options. Keytruda, with its broad spectrum of approved indications globally, is progressively becoming a cornerstone of cancer treatment, albeit with adoption rates influenced by country-specific healthcare policies, economic conditions, and patient access initiatives. The global Keytruda market was valued at US$ 27.09 billion in 2024 and is projected to reach nearly US$ 54.78 billion by 2032, growing at a CAGR of 9.20%. Within South America, countries like Argentina and Brazil are significant contributors to the regional market, with Argentina's Keytruda market alone projected to reach US$ 139.3 million by 2030. Brazil is projected to lead the regional Keytruda market in terms of revenue by 2030, highlighting its market strength.
This growth signifies the increasing adoption of immunotherapies in a region where the cancer burden is substantial and continues to rise.
Key Market Drivers and Trends:
Rising Cancer Prevalence: South America faces a significant and growing burden of cancer. According to the Pan American Health Organization (PAHO), cancer is the second leading cause of death in the Americas, with lung, breast, colorectal, and prostate cancers being among the most common. The increasing incidence of these cancers across the region directly fuels the demand for effective treatments like Keytruda. Lung cancer was the largest revenue-generating application globally for Keytruda in 2024, and this trend is reflected in the regional adoption.
Expanding Therapeutic Indications: Keytruda's global approvals for a wide array of cancers – including melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma, and cervical cancer – make it a versatile and highly sought-after drug. The continuous expansion of its label into new tumor types and treatment settings (e.g., adjuvant, neoadjuvant) further drives its market penetration in South America. Breast Cancer is projected to be the fastest-growing application segment for Keytruda, indicating future growth areas.
Growing Awareness and Adoption of Immunotherapy: Oncologists and healthcare professionals in South America are increasingly aware of the efficacy and long-term benefits of immunotherapy. Participation in global clinical trials and access to international scientific literature contribute to higher confidence in prescribing Keytruda. Educational initiatives by pharmaceutical companies and oncology societies further accelerate this adoption.
Improving Access and Reimbursement (Varying by Country): While challenges remain, several South American countries are making strides in improving access to high-cost innovative drugs. Countries like Brazil and Argentina have more developed public and private health systems that offer some level of reimbursement or funding for high-value oncology drugs. For instance, Brazil has a robust public health system (SUS) and a growing private insurance market that can facilitate access. However, in emerging markets within Latin America, affordability and access remain major obstacles, heavily influenced by government policies and economic factors.
Development of Subcutaneous Formulation: Merck's ongoing development of a subcutaneous (SC) formulation for Keytruda holds significant promise for South America. An SC version could reduce the burden of intravenous infusions, improve patient convenience, potentially decrease healthcare resource utilization (e.g., chair time in clinics), and make administration more feasible in settings with limited infrastructure, thereby expanding access.
Strategic Partnerships and Local Presence: Pharmaceutical companies are increasingly engaging in strategic partnerships with local distributors and healthcare providers to enhance their presence and improve the supply chain for specialized oncology drugs in the region.
Despite challenges such as price sensitivity, varying levels of public healthcare funding, and complex regulatory approval processes in different countries, the South America Keytruda Market is on a growth trajectory. The increasing cancer burden, coupled with a rising demand for advanced and effective treatments, ensures Keytruda's continued impact on oncology care across the continent. Addressing the challenges of affordability and equitable access will be key to unlocking the market's full potential.
About Market Research Future (MRFR)
Market Research Future (MRFR) is a global market research firm that provides comprehensive insights into market trends, drivers, challenges, and opportunities. We offer a broad range of market intelligence reports and consulting services to help businesses and enterprises in various industries make informed decisions.
Media Contact:
Market Research Future (MRFR)
Phone: +1-646-845-9312
Email: contact@marketresearchfuture.com
Website: marketresearchfuture